Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.
ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)
Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.
Treatment strategies for patients with lower-risk MDS are examined.
In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
5